Nivolumab/Relatlimab Shows PFS/OS Benefit Over Nivolumab in Melanoma
Source: Targeted Oncology, May 2023
Targeted Oncology: What data support the combination of nivolumab and relatlimab (Opdualag) for patients with metastatic melanoma?
MICHAEL B. ATKINS: The RELATIVITY-047 trial [NCT03470922]compared nivolumab at 480 mg and relatlimab 160 mg in a fixed-dose combination with nivolumab [Opdivo] monotherapy every 4 weeks, stratified by LAG-3 status, PD-L1 status, BRAF status, and American Joint Committee on Cancer melanoma stage.
The median was 63 years of age, which is typical for a melanoma study population. Not much older and certainly not much younger. Sixty percent were male, which is pretty typical.